Paragonix Technologies, Inc.’s Post

Organ scarcity poses a demanding challenge on a nation where more than 100,000 people wait for the possibility of a donor organ transplant. This morning, Newsweek asked Paragonix founder and CEO, Dr. Lisa Anderson, how optimizing today's technologies can make an impact. "While the state of transplantation is not without challenges, we can address many of them with the technology we have today," Dr. Anderson shared. "We owe it to patients waiting for a second chance to build on our progress and achieve even more through ongoing research, innovation, and collaboration across the industry." Read the full article on Newsweek: https://lnkd.in/eMmt_9_B https://lnkd.in/eAM3Eg_6

Organ scarcity poses a demanding challenge on a nation where more than 100,000 people wait for the possibility of a donor organ transplant. This morning, Newsweek asked Paragonix founder and CEO, Dr. Lisa Anderson, how optimizing today's technologies can make an impact. "While the state of transplantation is not without challenges, we can address many of them with the technology we have today," Dr. Anderson shared. "We owe it to patients waiting for a second chance to build on our progress and achieve even more through ongoing research, innovation, and collaboration across the industry." Read the full article on Newsweek: https://lnkd.in/eMmt_9_B #toronto

Discover the groundbreaking advancements in organ transplantation that are reshaping the landscape of medical science. This article explores the transformative role of perfusion devices ensuring that compromised organs are viable for transplantation and offering renewed hope to patients in need. Join the journey of progress during Donate Life Month as we celebrate the remarkable strides made possible by dedicated researchers and healthcare professionals. Watch the video attached in the article to know more: https://lnkd.in/d3en94k5 #HealthInsights #OrganDonation #TransplantTechnology #MedicalInnovation #DonateLifeMonth

As you may remember during the COVID-19 pandemic, logistical issues such as flight delays, travel bans, and supply chain disruptions made it difficult to deliver fresh donor samples. This jeopardized many patient graft transplantations, cell therapy treatments and infusions. Cryopreservation of cell-based products offers a safe and reliable alternative, when fresh samples are not available or very complex to obtain. Our NEW blog post explores the key benefits of shifting to cryopreserving cell-based products. Some life science organizations have continued to use cryopreservation long after the height of the pandemic. We think this adoption will continue to rise. What do you think? Read on to review the benefits: https://lnkd.in/eiRArSTE #cryopreservation #celltherapy #cellproducts #cells

RoosterBio is constantly striving to share new and interesting ideas through original blog articles, collaborative webinars, research publications, and more. With so much happening, there's a lot you may have missed. Check out our Top 5 Most Popular Blogs of 2023 below. And find more blogs on our website: https://hubs.ly/Q02dxHsr0 🔸Upstream, Downstream, & In Between: RoosterBio Collaborations Featured at ISEV, ISCT, & ASGCT > https://hubs.ly/Q02dxHYf0 🔸HUCPVCs – The “Champagne” of Human Umbilical Cord Cells? > https://hubs.ly/Q02dxKgh0 🔸When ChatGPT Meets hMSCs & Their Exosomes > https://hubs.ly/Q02dxH-30 🔸From Benchmark to Airborne: MISEV Guidelines Inspire Fledgling EV/Exosome Analytics Services > https://hubs.ly/Q02dxD1Q0 🔸Mitochondria Transplantation Therapy – It’s Farther Along Than You Think > https://hubs.ly/Q02dxKj50

Elevate post-kidney transplant care with Tutivia, a highly dependable tool. Validated in a prospective, blinded, multicenter and international study published in The American Journal of Transplantation, we designed this study to emulate the diverse patient population you see in your clinic every day. Why is this important? It means we can confidently deliver performance validation for Tutivia to clinicians around the world as an effective and essential tool in post-kidney transplant care knowing that it can deliver highly reproducible, reliable results every time. #ReliableEvenEarly #TutiviaDelivers #VRCI https://lnkd.in/ewzAaJzK

Strong study design in post-kidney transplant to build confidence with both patients and providers in Tutivia.

Join us at #NATCO where we'll be showcasing cutting-edge solutions that prioritize care, custody, and control while introducing a state-of-the-art communication center to streamline operations like never before! Here are three compelling reasons to stop by our booth: 1.Optimized Organ Transplant Logistics: Our innovative approach ensures the seamless transportation of organs, prioritizing safety and efficiency at every step of the journey. With our solutions, you can trust that organs reach their destination promptly, preserving their viability for transplantation. 2.Emphasis on Care, Custody, and Control: We understand the paramount importance of maintaining the integrity of each organ throughout the transportation process. Our meticulous attention to detail guarantees that every organ is handled with the utmost care, ensuring its viability and efficacy for transplantation. 3.State-of-the-Art Communication Center: Experience firsthand how our advanced communication center revolutionizes the way organ transplant logistics are managed. With real-time tracking, proactive monitoring, and instant communication capabilities, we empower healthcare professionals to coordinate seamlessly and respond swiftly to any situation. Don't miss out on this opportunity to learn more about how our solutions can transform organ transplant logistics for the better. Visit us at Booth 302 during the 49th NATCO Annual Meeting and let's discuss how we can collaborate to make a difference! #NORA #carecustodycontrol #transplantlogistics

📰Published in Nature Medicine, these findings underline the critical importance of infectious complications after CAR T cell therapy & support the comprehensive reporting of NRM, including specific causes &long-term outcomes Abstract➡️https://lnkd.in/giCJj3TJ #CART #mmsm #myeloma

3 weeks, 3 conferences...this final one is a doozy and one of my favorites on my schedule for the year. Looking forward to the Young Investigators Forum today, followed by the Controversies in Transplantation meeting for 3 days. #transplantation #MSLlife #alwayslearning